Summary
The present study involved the in vivo evaluation of orally administered guar gum-based colon-targeted tablet formulations of celecoxib (colon-targeted tablet-20 or colon-targeted tablet-30) as compared with an immediate release capsule in 15 human volunteers. Blood samples were obtained at different time intervals and the plasma concentration of celecoxib was estimated by reversed phase HPLC. The immediate release capsules of celecoxib might have disintegrated very fast in GI tract and absorbed quickly from stomach and small intestine thereby producing peak plasma concentration (Cmax of 478±57 ng/ml) within 3.8±0.1 h (Tmax). Though celecoxib could be seen in plasma after oral administration of colon-targeted tablet-20 or colon-targeted tablet-30 between 1 and 2 h, low levels of drug were observed upto 8h resulting in peak concentration (Cmax) of 78±6ng/ml or 88±15ng/ml at 10.5±1.9 h or 13.5±1.4 h (Tmax) respectively, whereas the immediate release capsules produced peak plasma concentration (Cmax) of 478±57 ng/ml at 3.8±0.1h (Tmax). Colon-targeted tablets showed decreased AUC0–∞, Cmax and absorption rate constant, prolonged absorption time (ta), and increased t1/2 in comparison with the immediate release capsules. The results of the study indicated that the guar gum-based colon-targeted tablets of celecoxib did not release the drug significantly in stomach and small intestine, but delivered to the colon resulting in a slow absorption of the drug and making it available for local action in the colon.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kudo T., Narisawa T., Abo S. (1980): Anti-tumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann., 71, 260–264.
Oshima M., Dinchuk J.E., Kargman S.L. (1996): Suppression of intestinal polysis in Ape delta 716 knock out mice by inhibition of cyclooxygenase-2 (COX-2). Cell., 87, 803–809.
Kawamori T., Rao C.V., Seibert K., Reddy B.S. (1998): Chemoprotective activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409–412.
Kalgutkar A.S., Crews B.C., Rowlinson S.W. (1998): Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science., 280, 1268–1270.
Janne P.A., Mayer R.J. (2000): Primary care: Chemoprevention of colorectal cancer. N. Engl. J Med., 342, 1960–1968.
Steinbach G., Lynch P.M., Phillips R.K.S. et al. (2000): The Effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946–1952.
Reddy B.S., Hirose Y., Lubet R., Steele V. et al. (2000): Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis. Cancer Res., 60, 293–297.
Needleman P., Isakson P.C. (1998): Selective inhibition of cyclooxygenase-2. Science and Medicine., 1, 26–35.
Krishnaiah Y.S.R., Satyanarayana V., B Dinesh Kumar. et al. (2002): Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J. Drug Target., 10, 247–254.
Rama Prasad Y. V., Krishnaiah Y.S.R., S. Satyanarayana. (1998): In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J. Control. Rel., 51, 281–287
Gibaldi M., Perrier, D. (1990): Pharmacokinetics, 2nd edition, Marcel Dekker, New York.
Ritschel W.A. (1986): UC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis. Methods and findings of Experimental Clinical Pharmacology. 8: 633–640.
Krishnaiah Y.S.R., Satyanarayana S., Rama Prasad Y.V. et al. (1998): Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy subjects. J. Control. Rel., 55, 245–252.
Krishnaiah Y.S.R., Satyanarayana S Rama Prasad Y.V. et al. (1998): Evaluation of guar gum as a compression coat for drug targeting to colon. Int. J. Pharm., 171, 137–146.
Krishnaiah Y.S.R., Satyanarayana S., Rama Prasad Y.V. et al. (1999): Studies on guar gum compression coated 5-amino salicylic acid tablets for Colon-specific drug delivery. Drug Dev. Ind. Pharm., 25, 651–657.
Krishanaiah Y.S.R., Veer Raju P., Dinesh Kumar B. et al. (2001): Development of colon targeted drug delivery systems for mebendazole. J. Control. Rel., 77, 87–95.
Krishnaiah Y.S.R., Bhaskar Reddy P.R., Satyanarayana V. et al. (2002): Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int. J. Pharm., 236, 43–55.
Krishnaiah Y.S.R., Satyanarayana V., Dinesh Kumar B. et al. (2002): In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur. J. Pharm. Sci., 16, 185–192.
Krishnaiah Y.S.R., Indira Muzib Y., Srinivasa Rao G. et al. (2002). Design and In vitro evaluation of oral colon targeted drug delivery systems for tinidazole. J. Drug Target., (accepted).
Grahnen A. (1984): Design of bioavailability studies. Pharm. Int., 5, 100–103.
Westlake W.J. (1988) In: K.E. Peace (ed.), Biopharmaceutical statistics for drug development, Marcel Dekker, New York, 329.
RobertsII L.J., Morrow J.D. (2001): Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics (10th edition), McGraw Hill, Medical Publishing Division, New York, 715.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krishnaiah, Y.S.R., Satyanarayana, V., Dinesh Kumar, B. et al. In vivo evaluation of guargum-based colon-targeted oral drug delivery systems of celecoxib in human volunteers. Eur. J. Drug Metab. Pharmacokinet. 27, 273–280 (2002). https://doi.org/10.1007/BF03192338
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03192338